GIPR rs1800437 and Tirzepatide: What the 2026 Nature Pharmacogenomics Study Found
In April 2026, a Nature GWAS of 27,885 GLP-1 medication users found GIPR rs1800437 associated with outcomes specifically in tirzepatide users — not in GLP-1-only agonist users. This article explains what that finding means, why the dual-receptor distinction matters, and why the PlexusDx Precision Peptide Genetic Test directly genotypes this SNP across 34 weight management insights.
GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

